Cervical polyp

Summary

Cervical polyp (MONDO:0000751) is a disease with 1 GWAS associations across 3 studies. A subtype of cervix disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• GWAS associations: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cervical polyp
Mondo ID	MONDO:0000751
DOID	DOID:0060325
ICD-10-CM	N84.1
ICD-11	396198272
NCIT	C2939
SNOMED CT	65576009
UMLS	C0007855
MedGen	507540
Anatomy (UBERON)	UBERON:0000002
Is cancer (heuristic)	no

Also known as: adenomatous polyp of cervix · adenomatous polyp of the cervix · adenomatous polyp of the uterine cervix · adenomatous polyp of uterine cervix · cervical polyp · cervical polyp (disease) · cervix adenomatous polyp · cervix polyp · cervix uteri adenomatous polyp · cervix uteri polyp · polyp of cervix · polyp of cervix uteri · polyp of the cervix · polyp of the cervix uteri · polyp of the uterine cervix · polyp of uterine cervix · uterine cervix adenomatous polyp · uterine cervix polyp

Data availability: 1 GWAS association (3 studies) · 1 HPO phenotype.

Disease family

This is a subtype of cervix disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › uterine disorder › cervix disorder › cervical polyp

Related subtypes (8): hypertrophic elongation of cervix, cervicitis, cervix endometriosis, uterine cervix leukoplakia, cervical incompetence, cervical metaplasia, cervix erosion, uterine cervix neoplasm

Subtypes (1): cervical fibroepithelial polyp

Genetics & variants

GWAS landscape

1 GWAS associations across 3 studies. Top hits map to 0 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs146834132	4e-09	MEI4 - IRAK1BP1	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90436511	Zhou W	2018	3,450	396,384	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90482278	Verma A	2024	421	32,103	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90651369	Liu TY	2025	388	126,166	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	1

MAF distribution

Bucket	Variants
common (>=0.05)	0
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	1

Functional consequences

Consequence	Count
intergenic_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs146834132	6	78734867	C>T		intergenic_variant	MEI4 - IRAK1BP1	4e-09	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.